305 related articles for article (PubMed ID: 33400975)
1. Passive immunization and its rebirth in the era of the COVID-19 pandemic.
Pavia CS; Wormser GP
Int J Antimicrob Agents; 2021 Mar; 57(3):106275. PubMed ID: 33400975
[TBL] [Abstract][Full Text] [Related]
2. Passive immune therapies: another tool against COVID-19.
Estcourt LJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):628-641. PubMed ID: 34889410
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.
Canedo-Marroquín G; Saavedra F; Andrade CA; Berrios RV; Rodríguez-Guilarte L; Opazo MC; Riedel CA; Kalergis AM
Front Immunol; 2020; 11():569760. PubMed ID: 33362758
[TBL] [Abstract][Full Text] [Related]
4. Potential therapeutic options for COVID-19: an update on current evidence.
Niknam Z; Jafari A; Golchin A; Danesh Pouya F; Nemati M; Rezaei-Tavirani M; Rasmi Y
Eur J Med Res; 2022 Jan; 27(1):6. PubMed ID: 35027080
[TBL] [Abstract][Full Text] [Related]
5. Emerging treatment strategies for COVID-19 infection.
Gavriatopoulou M; Ntanasis-Stathopoulos I; Korompoki E; Fotiou D; Migkou M; Tzanninis IG; Psaltopoulou T; Kastritis E; Terpos E; Dimopoulos MA
Clin Exp Med; 2021 May; 21(2):167-179. PubMed ID: 33128197
[TBL] [Abstract][Full Text] [Related]
6. Perspective on the Role of Antibodies and Potential Therapeutic Drugs to Combat COVID-19.
Tandon S; Aggarwal A; Jain S; Shukla S; Chaudhary S
Protein J; 2020 Dec; 39(6):631-643. PubMed ID: 33034824
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
8. Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?
Gunjegaonkar SM; Shanmugarajan TS; Arunsundar M; Arjun UVNV; Devi K; Wankhede SB; Ravichandiran V
Therapie; 2021; 76(4):335-345. PubMed ID: 34238584
[TBL] [Abstract][Full Text] [Related]
9. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S; Rosik J; Lechowicz K; Machaj F; Szostak B; Przybyciński J; Lorzadeh S; Kotfis K; Ghavami S; Łos MJ
Drug Resist Updat; 2021 Dec; 59():100794. PubMed ID: 34991982
[TBL] [Abstract][Full Text] [Related]
10. Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2.
Bormann M; van de Sand L; Witzke O; Krawczyk A
Klin Monbl Augenheilkd; 2021 May; 238(5):569-578. PubMed ID: 34020485
[TBL] [Abstract][Full Text] [Related]
11. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
12. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
[TBL] [Abstract][Full Text] [Related]
13. Passive immunization: Paradoxical and traditional method for new pandemic challenge COVID-19.
Iftikhar A; Jabeen F; Manzoor M; Younis T; Shaheen M
Acta Microbiol Immunol Hung; 2020 Jul; 67(2):87-90. PubMed ID: 32619190
[TBL] [Abstract][Full Text] [Related]
14. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
Front Immunol; 2021; 12():711915. PubMed ID: 34276706
[TBL] [Abstract][Full Text] [Related]
16. Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series.
Rüfenacht S; Gantenbein P; Boggian K; Flury D; Kern L; Dollenmaier G; Kohler P; Albrich WC
Infection; 2022 Jun; 50(3):783-790. PubMed ID: 35426564
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
[TBL] [Abstract][Full Text] [Related]
18. Perspectives for immune plasma treatment of COVID-19.
Sayinalp B; Çinar OE; Haznedaroğlu İC
Turk J Med Sci; 2021 Feb; 51(1):1-9. PubMed ID: 32718128
[TBL] [Abstract][Full Text] [Related]
19. [Value of convalescent plasma in the therapy of COVID-19].
Körper S; Seifried E; Schrezenmeier H
Dtsch Med Wochenschr; 2023 Mar; 148(7):423-426. PubMed ID: 36940693
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Measures for the Novel Coronavirus: A Review of Current Status and Future Perspective.
Shahverdi M; Darvish M
Curr Mol Med; 2021; 21(7):562-572. PubMed ID: 33272178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
